JPMorgan International Research Enhanced Equity ETF
J.P. Morgan Exchange-Traded Fund Trust · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
JPMorgan International Research Enhanced Equity ETF is an actively managed developed international equity ETF.
- Asset class
- Equity
- Region
- Developed international
- Management
- Actively managed
- Fund type
- ETF
Fund profile
As filed in the prospectus · 2026 Q1
The Fund seeks to provide long-term capital appreciation.
The fund invests at least 80% of its assets in equity securities of developed-market foreign companies, seeking to outperform the MSCI EAFE Index while maintaining similar risk characteristics. The adviser uses fundamental research to identify securities it deems undervalued or fairly valued within each sector, typically overweighting attractive holdings and underweighting or avoiding those deemed unattractive. Because the fund may invest substantially in a single country and holds securities not included in the Index, its sector and geographic exposures may diverge from the benchmark.
| Share class | Gross | Net |
|---|---|---|
| JIRE | 0.29% | 0.24% |
Net is what a holder pays after the adviser's contractual waiver; gross is before it. A waiver can expire.
Portfolio turnover 25.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 98.77% |
| Cash & short-term | 3.36% |
Latest quarter
What changed since the fund's previous filing
Largest new: Roche Holding AG, Banco de Sabadell SA, Reckitt Benckiser Group plc, KDDI Corp., Thales SA, Central Japan Railway Co., Ebara Corp., Telia Co. AB
Largest exited: Roche Holding AG, Reckitt Benckiser Group plc, East Japan Railway Co., AIB Group plc, Kobe Bussan Co. Ltd., Equinor ASA, NN Group NV, Shimano, Inc.
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| — | ASML Holding NV | 3.17% | $1,445.55 | $335.03M | 231.8K |
| — | JPMorgan Securities Lending Money Market Fund | 2.77% | — | $293.53M | — |
| — | AstraZeneca plc | 2.06% | $189.72 | $217.77M | 1.1M |
| — | Siemens AG | 1.67% | $297.16 | $176.94M | 595.4K |
| — | Shell plc | 1.60% | $45.47 | $168.92M | 3.7M |
| — | Allianz SE | 1.43% | $456.73 | $151.83M | 332.4K |
| — | HSBC Holdings plc | 1.43% | $18.40 | $151.46M | 8.2M |
| — | Nestle SA | 1.40% | $101.24 | $148.12M | 1.5M |
| — | Roche Holding AG | 1.27% | $407.50 | $134.86M | 330.9K |
| — | Banco Santander SA | 1.21% | $12.20 | $128.24M | 10.5M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.
Top 10 positions are 18.01% of net assets, top 25 33.91%, across 219 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free